Search Results 11-20 of 7557 for younkin

  1. Publications - Wei Liu, Ph.D. - Mayo Clinic

    Ding X, Younkin JE, Shen J, Bues M, Liu W. A critical review of the practices of proton daily quality assurance programs. Ther Radiol Oncol. 2021 Dec; 5:22.

  2. Publications - Nilufer Taner, M.D., Ph.D. - Mayo Clinic

    ... Younkin SG, Carrasquillo MM, Duara R, Graff-Radford NR, Pottier C, Ertekin-Taner N, Ross OA, Rademakers R, Dickson DW, Murray ME. The SERPINA5 coding ...

  3. Methods Development - Drug Discovery, Design and Optimization for Novel Therapeutics: Thomas Caulfield - Mayo Clinic Research

    ... Younkin SG, Fryer JD, Wang H, Han X, Frieden C, Dickson DW, Ross OA, Bu G. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia ...

  4. Publications - Daniel W. Mundy, Ph.D. - Mayo Clinic

    ... Younkin JE, Stoker JB. Automation of routine elements for spot-scanning proton patient-specific quality assurance. Med Phys. 2019 Jan; 46 (1):5-14 Epub 2018 ...

  5. clinicaltrials gov.

  6. Publications - Yixiu Kang, Ph.D. - Mayo Clinic

    Shen J, Tryggestad E, Younkin JE, Keole SR, Furutani KM, Kang Y, Herman MG, Bues M. Technical Note: Using experimentally determined proton spot scanning ...

  7. John M. Tokish, M.D. - Mayo Clinic Faculty Profiles

    Mayo Clinic researcher John M. Tokish, M.D., explores shoulder instability, rotator cuff healing and shoulder arthroplasty.

  8. Thanai Pongdee, M.D. - Mayo Clinic Faculty Profiles

    The research of Mayo Clinic's Thanai Pongdee, M.D., focuses on eosinophil-associated disorders and mast cell diseases.

  9. A Study to Evaluate S-600918 in Adults With Refractory Chronic Cough - Mayo Clinic

    About this study. The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating ...

  10. A Study of Chemotherapy in Patients with Immunoglobulin Light (or Heavy) Chain Amyloidosis - Mayo Clinic

    About this study. The aims of this prospective observational study will be to include all patients with systemic AL amyloidosis regardless of age or disease ...